The EMD-RX5 is pretty amazing when they line it up against other...

The EMD-RX5 is pretty amazing when they line it up against other CBD preps and Epidyolex as an FDA approved product.

When you talk to people looking for medicinal cannabis/CBD etc one of the first concerns they mention is driving - getting drug tested and going positive with THC. If you drive with impairment and its detectable, potentially you end up charged, your insurance wont pay if you have an accident etc etc. You could probably extend that to being tested by your employer in certain industries and blah blah blah.

Our product contains no detectable THC, meets the FDA requirements unlike so many others, has improved bioavailability and in a preferred dose form. Without getting too far ahead of ourselves (myself) you could imagine a time when the TGA/FDA reign in some of the "less pure" products which would only further open the market to our product. Page 5 of the presentation slips in "partnership ready" as well, so I think there is some understanding that IF its to emerge as a global market leading product, it's going to need some help. I don't have a problem with that at all, much better than someone big with an inferior product just buying the company to protect their own product dominance.

So much to like about the EMD-RX, I have said it a few times that I know the MDMA catalogues are important and ongoing in preclinical studies and realistically still a long, long way from standard of care for PTSD etc, but I really want to see them getting into the commercialisation of the RX5 and RX7 down the track. They've not paid the price many seeking capital have in terms of SP with holders staying holders it seems, probably because the placement was explicitly to invest back into growth and not just because in case we run out of money on day to day cash burns.